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Mitochondrial oxidative damage 
Neuroprotection 
A B S T R A C T   
The extent that age-dependent mitochondrial dysfunction drives neurodegeneration is not well understood. This 
study tested the hypothesis that mitochondria contribute to spinal cord injury (SCI)-induced neurodegeneration 
in an age-dependent manner by using 2,4-dinitrophenol (DNP) to uncouple electron transport, thereby increasing 
cellular respiration and reducing reactive oxygen species (ROS) production. We directly compared the effects of 
graded DNP doses in 4- and 14-month-old (MO) SCI-mice and found DNP to have increased efficacy in mito-
chondria isolated from 14-MO animals. In vivo, all DNP doses significantly exacerbated 4-MO SCI neuro-
degeneration coincident with worsened recovery. In contrast, low DNP doses (1.0-mg/kg/day) improved tissue 
sparing, reduced ROS-associated 3-nitrotyrosine (3-NT) accumulation, and improved anatomical and functional 
recovery in 14-MO SCI-mice. By directly comparing the effects of DNP between ages we demonstrate that 
mitochondrial contributions to neurodegeneration diverge with age after SCI. Collectively, our data indicate an 
essential role of mitochondria in age-associated neurodegeneration.   
1. Introduction 
Metabolic processes shift throughout a lifespan as an inevitable 
consequence of aging (a thorough review of how aging affects brain 
metabolism can be found in Mattson and Arumugam (2018)). Under-
lying many age-associated metabolic changes is a progressive deterio-
ration in mitochondrial function (Gruber et al., 2013, 2008; Srivastava, 
2017). Mitochondria are the primary producers of energy and play vital 
roles in maintaining health and homeostasis of cellular functions. It is, 
therefore, not surprising that mitochondrial dysfunction significantly 
contributes to aging and disease progression (Gruber et al., 2008; Sri-
vastava, 2017). Specifically, a biproduct of mitochondrial respiration is 
the generation of reactive oxygen species (ROS), which under normal 
physiological conditions function in vital cell signaling. In excess how-
ever, increases in ROS drive pathophysiological processes such as pro-
tein and lipid oxidation that can induce senescence and accelerate 
disease pathology (Birla et al., 2020; Cherubini et al., 2020; Hall et al., 
2015; Ricke et al., 2020; Saxena et al., 2019; Zhang et al., 2019). 
An increase in ROS production from mitochondria is a known 
consequence of aging (Yonutas et al., 2015) and is further exacerbated 
by several neurodegenerative or neurotraumatic conditions (Birla et al., 
2020; Cherubini et al., 2020; Pandya et al., 2007; Ricke et al., 2020). 
One way ROS is generated by mitochondria is when resistance to elec-
tron transfer increases, which induces slippage of electrons onto soluble 
oxygen forming the free radical superoxide (Suski et al., 2012; Zhao 
et al., 2019). Downstream reactive products of superoxide induce pre-
dictable and detectable cellular damage to lipids (4-hydroxynonenol, 4- 
HNE), proteins (3-Nitrotyrosine, 3-NT, when reacted with nitric oxide), 
and DNA, all of which accumulate with age and disease. Consequently, 
therapeutic strategies aimed at ameliorating mitochondrial dysfunction 
have emerged as promising approaches to mitigate or slow neuro-
degeneration occurring with age and disease or trauma (Caldeira da 
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Silva et al., 2008; Yonutas et al., 2016). However, the extent to which 
mitochondrial changes with age contribute to, or confound, neuro-
degeneration and recovery is not well understood. 
Increases in mitochondrial membrane potential are tightly associ-
ated with increased resistance to electron flow and accelerated ROS 
formation (Zhao et al., 2019). Under normal homeostatic conditions, 
increased ROS generated by mitochondria induce feedback regulation of 
mitochondrial regulatory proteins such as uncoupling proteins (UCPs) 
(Ježek et al., 2015; Pecqueur et al., 2001). UCPs reduce mitochondrial 
membrane potential, allowing flow of protons back into the mitochon-
drial matrix, effectively decreasing respiratory resistance and mitigating 
superoxide leak during electron transport (Zhao et al., 2019). Although 
decreasing mitochondrial ROS may appear beneficial to cellular health, 
increasing permeability of protons through the inner mitochondrial 
membrane uncouples respiration from ATP production (Geisler et al., 
2016). In compromised environments such as in neurodegeneration or 
neurotrauma, mitochondria are therefore engaged in a competing bal-
ance to meet increased cellular energy demands while regulating ROS 
over-production. How this homeostatic imbalance is regulated with age 
in health and disease is not well understood. Based upon the potential 
double-edged sword of pharmacological uncouplers, in the current study 
we used the uncoupling agent 2,4-dinitrophenol (DNP) to study age- 
dependent mitochondrial function after spinal cord injury (SCI). 
Mitochondria that have been injured following SCI increase ROS 
production which exacerbate neurodegeneration and tissue damage (Jin 
et al., 2004; McEwen et al., 2011; Pandya et al., 2007; Patel et al., 2009). 
This secondary injury after SCI can propagate for weeks-to-months 
following the primary insult. Mitigating respiratory ROS production 
immediately post-injury, or ROS generated from inflammatory non- 
mitochondrial derived sources, have proven effective and limits sec-
ondary injury (Impellizzeri et al., 2011; Jin et al., 2004; Khayrullina 
et al., 2015; Pandya et al., 2007; Patel et al., 2009; Zhang et al., 2019). 
How mitochondria contribute to a progressive neurodegeneration 
observed after SCI is less well understood, and almost nothing is known 
about how age effects this process. A lack of knowledge about how aging 
effects SCI is of growing concern as a shift in the average age at time of 
SCI has progressed from 28 years of age to 42 since the 1970’s (NSCISC, 
2013). The prominent role of mitochondria in both aging and SCI has 
clinical implications since the efficacy of mitochondrial-based pharma-
cotherapies for neurotrauma may vary with age. This study utilized the 
progressive neurodegeneration occurring following SCI to interrogate 
how age affects mitochondrial regulation of secondary injury and re-
covery, using graded doses of DNP. 
Collectively, we observed age-dependent effects on the function of 
isolated mitochondria after SCI and DNP treatment. In vivo, dose- 
response DNP treatment produced age-divergent effect on ROS accu-
mulation, neurodegeneration, and functional recovery at multiple time 
points after SCI in 4- and 14-month old (MO) mice. Specifically, 14-MO 
mice benefitted from DNP treatment while DNP worsened outcomes in 
4-MO mice. Collective results demonstrate that age-associated changes 
in mitochondrial function have profound effects on injury-induced 
neurodegeneration and highlight the importance of age as a biological 
variable in the treatment and progression of central nervous system 
disorders. 
2. Material and methods 
2.1. Animals, surgical procedures, and DNP delivery 
All procedures followed institutional and national guidelines for the 
care and use of laboratory animals as approved by the University of 
Kentucky’s Animal Care and Use Committee. Female C57/Bl6 mice of 
age 4- (n = 63; Jackson Laboratories) and 14-months old (MO) (n = 67; 
National Institute for Aging) received surgical laminectomy followed by 
a 60 kdyn T9 contusion SCI (Infinite Horizons Impactor) as previously 
described (Zhang et al., 2016), or laminectomy only (n = 12). Mice of 
age 4- and 14-MO were chosen as the most phylogenetically comparable 
ages to represent the shift in clinical demographics from young adults to 
middle age at time of SCI (Dutta and Sengupta, 2016; Semple et al., 
2013). Further, a 60 kdyn injury was chosen empirically based on pre-
vious work demonstrating that a 50 kdyn injury is too mild to sustain 
detectable functional deficits in 4-MO mice, while a 75 kdyn injury is too 
severe in 14-MO mice, resulting in increased mortality and an inability 
to weight support during objective functional analysis. Mice were 
anesthetized using intraperitoneal (IP) injections of ketamine (100.0 
mg/kg) and xylazine (10.0 mg/kg), and received analgesic (Buprenex 
SR, 1.0 mg/kg day of surgery), antibiotic (Enrofloxacin, 5.0 mg/kg for 5 
days), and saline (1.0 mL/day for 5 days) support following surgery. All 
mice were group housed for the duration of the study on a 14 h light/10 
h dark cycle. Manual bladder evacuations were performed 2×/day for 
the duration of the study. 
Mice were randomly assigned to receive DNP (Sigma Aldrich CO. St. 
Louis, MO; 1.0-, 2.5-, or 5.0-mg/kg), or vehicle (1% dimethyl sulfoxide; 
DMSO), which were delivered via intraperitoneal (IP) bolus injections 
(10 μL per g body weight) 30 min post-injury then daily for up-to 7 days. 
Stock 50.0 mg/mL concentrations of DNP were dissolved in DMSO and 
diluted in sterile phosphate buffered saline (0.01 M; PBS) immediately 
before use. Throughout the following three major experiments (1. Ex 
vivo mitochondrial analyses, 2. 7-day survival, 3. 28-day survival) a total 
of n = 4 4-MO mice, and n = 9 14-MO mice were lost due to premature 
morbidity or mortality or surgical complications. Respectively for 4- and 
14-MO mice, n = 1- and 2-mice died overnight after SCI; n = 2- and 5- 
mice died under anesthesia for unknown reasons; n = 1- and 1-mice 
were excluded based upon a priori exclusion criteria for abnormal 
impact parameters indicative of a bone hit or spinal movement at the 
time of injury; and n = 0- and n = 1-mice were euthanized two days prior 
to the end of study due to a major open and untreatable skin wound; the 
spinal cord from this mouse was included in histology and did not vary 
from others in group. The cause of mortality remains unknown for the 
three mice that died overnight after receiving SCI. Two of the three mice 
received a 5.0-mg/kg dose of DNP, while the third received a 1.0-mg/kg 
dose, therefore toxicity from DNP may be possible. All other mice 
experiencing mortality under anesthesia died prior to delivery of DNP. 
Supplementary Table 1 contains lists of final sample sizes used for all 
groups in all outcomes. 
2.2. Ex vivo mitochondrial response to DNP 
Mitochondria were isolated as previously described (Brown et al., 
2004) from 4- and 14-MO sham, or SCI-treated mice at 3- and 7-days 
post-injury (dpi). Briefly, mice were euthanized using CO2 followed by 
rapid decapitation. A 7-mm section of cord surrounding the lesion was 
quickly isolated and mechanically homogenized in respiration buffer. 
Tissue suspension was centrifuged at 1300 g to pellet debris, followed by 
collecting the supernatant and pelleting crude mitochondria at 13,000 g. 
Crude mitochondrial extract was suspended in respiration buffer and 
synaptic mitochondrial fractions were liberated using nitrogen 
bombing. Crude mitochondria were standardized based on protein 
content and evaluated for oxygen consumption rate (OCR) on the Sea-
horse (Seahorse XFe96 Analyzer; Agilent Technologies, Inc.; Santa 
Carla, CA) as previously described (Patel et al., 2009). The sensitivity of 
mitochondria to uncoupling was performed using pre-loaded auto-in-
jection ports to administer 1-, 10-, or 100-μM DNP in series and the 
change in OCR was obtained. Next, to perform a mitochondrial stress 
test, mitochondria were isolated from sham or vehicle-treated SCI-mice, 
as well as SCI-mice treated with 1.0 mg/kg DNP for 3- or 7-dpi. All 
mitochondrial experiments were initiated by treating wells with 5 mM 
Pyruvate, 2.5 mM Malate, and 1.0 mM ADP to drive State III respiration. 
Mitochondrial stress tests proceeded as previously described (Sauerbeck 
et al., 2011), using sequential delivery of Pyruvate/Malate/ADP (State 
III), Oligomycin (State IV), FCCP (State VCI), and Rotenone/Succinate 
(State VCII) to test different respiratory states. Experiments were 
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performed using 2–3 technical replicates per biological sample (n = 3/ 
group) depending upon auto-injecting success. 
2.3. Functional analysis 
Prior to SCI all mice were acclimated to testing paradigms including 
an open field for the Basso mouse scale (BMS; (Basso et al., 2006)) and 
the horizontal ladder (Cummings et al., 2007). Functional abilities were 
assessed after SCI using the BMS at 1-, 3-, 7-, 14-, 21-, and 28-dpi. 
Horizontal ladder was tested prior to injury and at 28-dpi for animals 
capable of performing at least coordinated stepping. This resulted in 
exclusion of 2 vehicle-treated 14-MO mice from analysis for an inability 
to step. To analyze horizontal ladder, video was captured from under-
neath as mice traversed a small 1.0 m ladder containing evenly spaced 
rungs. Misplaced hindlimb steps resulting in foot-slips beyond the plane 
of rungs were analyzed from video acquisition. Two reviewers who were 
blinded to experimental groups were used to assign BMS scores and one 
reviewer counted foot-slips on the horizontal ladder. 
2.4. Histological outcomes 
2.4.1. Tissue preparation 
At 7- and 28-dpi, vehicle and DNP-treated mice were anesthetized 
with a lethal dose of ketamine, exsanguinated using 0.1 M PBS, and 
perfused using 4% formaldehyde (Thermo Fisher Scientific, Waltham, 
MA). Spinal cord segments were collected, post-fixed in 4% formalde-
hyde for 2 h at room temperature, incubated overnight in 0.2 M phos-
phate buffer, then dehydrated with 30% sucrose (Sigma Aldrich CO., St. 
Louis, MO) at 4 ◦C. Spinal cords were placed side by side in cryomolds in 
sets of 4–5 cords/block in Optimal Cutting Temperature Compound 
(OCT), and frozen on dry ice. Spinal cords were arranged in a random 
order while ensuring at least one cord per group was frozen in each 
block. Sections were cut in the transverse plane at a 10-μm thickness and 
mounted in serial order, with 100 μm between serial sections on a slide. 
Prior to immunolabeling all slides were processed using heat-mediated 
antigen retrieval in 0.1 M sodium citrate buffer (pH 6.0) at 80 ◦C for 
5 min. 
Each set of immunolabeling, imaging, and analysis was performed 
for all animals in a single cohort, using identical staining, imaging 
acquisition, and analysis settings. Images were acquired using Zeiss 
Axioscan (model Z1, Carl Zeiss AG., Oberkochen, GE) and analyzed 
using Halo software (Indica Labs, Albuquerque, NM). Histology and 
immunohistochemistry was performed by individuals blind to group 
inclusion as follows. 
2.4.2. Tissue sparing and axon sprouting 
Slides were stained with eriochrome cyanine (EC; Sigma Aldrich CO., 
St. Louis, MO) for myelin and counterstained with fast red (nuclei) at 7- 
dpi, or immunolabeled for axons using neurofilament 200 kD (1:2500; 
NFH; Aves Labs Inc., Davis, CA) at 28-dpi. Immunolabeling was visu-
alized using 3,3′-diaminobenzidine (DAB; Vector Laboratories, Inc., 
Burlington, CA) as a chromogen. To analyze lesion areas, regions of 
spared tissue were traced, and areas were obtained. Tissue was consid-
ered spared based on macro structure morphology, evident by the 
clearly stained presence of white matter, or gray matter containing 
neurons and organized axonal architecture; tissue sections at the lesion 
epicenter typically have no spared gray matter and only a small rim of 
spared white matter. Spared tissue was assessed in each section to 
identify the section containing the least amount of spared tissue, which 
was used to define the lesion epicenter. All histological analyses were 
performed with respect to this defined epicenter. Due to a dynamic 
nature of lesion volumes at 7-dpi, the epicenter was used as a single 
predictor of tissue sparing for purposes of identifying an optimal dose for 
behavioral studies. At 28-dpi tissue sparing was analyzed every 100 μm 
for 700 μm rostral and caudal to the lesion. Tissue sparing at the lesion 
epicenter was compared between groups, as well as total sparing 
throughout all measured sections. 
Axon sprouting was analyzed within the lesion at 28-dpi using a 
staining threshold to detect DAB labeled axon filaments. The average 
proportion of positive labeled pixels to lesion area was analyzed in 3 
sections surrounding the epicenter per animal and used for comparison 
between groups. 
2.4.3. Reactive nitrogen species accumulation 
Reactive nitrogen species (RNS) damage was assessed at 7-dpi using 
immunolabeling against 3-nitrotyrosine (3-NT; 06-284; 1:2000; Sigma 
Aldrich CO., St. Louis, MO), as a measure of protein nitration (Carrico 
et al., 2010). To analyze 3-NT labeling, tissue sections up to 1-mm 
rostral and caudal to the epicenter were traced and a threshold was 
created to exclude non-positively labeled pixels from analysis. A 
threshold for determining positive pixel density was set based on tissue 
containing no 3-NT labeling from a 4-MO mouse section. No 3-NT la-
beling was performed at 28-dpi as increases in 3-NT have been reported 
to return to near-baseline conditions before 14-dpi (Carrico et al., 2010). 
2.4.4. Neuronal survival 
Neuronal sparing was assessed using immunolabeling against 
neuronal nuclei (NeuN; NBP1-77686; 1:4000; Novus Biologicals, 
Centennial, CO). Neuron viability was determined by tracing around the 
ventral horns of tissue sections and applying a particle counting algo-
rithm available on the Halo software. Parameters were set to identify 
neurons based on density, circularity, size, and contrast. Neuron counts 
from every other section between 500 μm rostral and caudal to the 
epicenter was summed and used to analyze 7-dpi tissue, and every 
section between 500 μm rostral and caudal to the epicenter was summed 
for 28-dpi tissue. 
2.5. Statistics 
Statistical modeling was performed in collaboration with University 
of Kentucky’s interdepartmental Applied Statistics Laboratory (ASL). 
General linear models were created to determine the effects of age, dose, 
and injury when appropriate. When comparing between ages was 
appropriate two- or three-way analysis of variance (ANOVA) was used. 
This includes analysis of ex vivo mitochondrial experiments, propor-
tional area of 3-NT labeling, and horizontal ladder using two-way 
ANOVA, as well as analysis of motor functions on BMS and BMS sub- 
scores using three-way ANOVA with repeated measures. Because spi-
nal cord size increases with age, outcomes dependent on absolute tissue 
area (sparing) and cell counts (neuron survival) were analyzed using 
within age-group comparisons with one-way ANOVA or two-way 
repeated measures ANOVA when appropriate. To directly compare 
outcomes between ages, values of DNP treated groups were normalized 
to mean values of within-age vehicle treated groups and treatment ef-
fects were compared between ages using two-way ANOVA. Dunnett’s 
pair-wise comparisons were made to limit analysis within ages and be-
tween vehicle and DNP-treated groups. Sidak’s pair-wise comparisons 
were used to compare between-group treatment effects when normal-
ized to vehicle controls. During analysis of neuron counts at 7-dpi, a 
single outlier was found using Grubbs’ analysis (value = 81; G = 1.737; 
p < 0.05) in the 4-MO 5.0-mg/kg/day DNP treatment group and was 
removed from analysis. No other outliers were identified. Statistical 
support was obtained from ASL to analyze BMS and BMS sub-scores due 
to the non-normal repeated measures nature of BMS sub-score data. BMS 
score models adjusted for the Day 1 score and BMS sub-scores were 
normalized by using a square root transformation of the change from 
Day 3. BMS analyses were completed using SAS 9.4 (SAS Institute, Cary, 
NC). All other analyses were completed using Prism v. 8.0 (Graphpad, 
San Diego, CA). Animal numbers for in vivo experiments were estimated 
by power analyses (1-β = 0.80; α = 0.05; one-way ANOVA) using 
standard deviations from pilot studies, as well as estimated effects from 
prior experiments in our lab investigating effects of age on treatment 
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efficacy using antioxidant therapies (Zhang et al., 2019). For behavioral 
outcomes n = 10 was predicted sufficient to power BMS analyses, while 
n = 5 was estimated for histological tissue sparing. For ex vivo mito-
chondrial experiments, routine use of n = 3 with 3 technical replications 
has proven sufficient power in prior experiments from our group 
(Yonutas et al., 2015). 
3. Results 
3.1. Effects of mitochondrial uncoupling are age-dependent 
We first set out to determine if age and SCI affect mitochondrial 
function. Specifically, mitochondria were isolated from spinal cords 
with or without (sham) moderate thoracic T9 contusion (60 kdyn) SCI. 
OCR of isolated mitochondria was examined with the Seahorse bio-
analyzer to determine effects of uncoupling using graded doses of DNP. 
High DNP doses (100.0 μM) were used to completely uncouple mito-
chondria, revealing significant SCI induced impairments in maximal 
respiratory capacity at 3- (F(1,8) = 5.94, p < 0.05; Fig. 1A) but not 7-days 
post-injury (dpi; F(1,8) = 0.66, p = 0.43; Fig. 1B). Surprisingly, age did 
not exacerbate mitochondrial dysfunction after SCI when completely 
uncoupled (Fig. 1). This SCI impairment of mitochondrial function is 
indicative of an impaired capacity for energy production that can last at 
least 3-, but not longer than 7-dpi. 
Next we simulated mild uncoupling effects, which have been proven 
safe for use in vivo (Jin et al., 2004; Maragos et al., 2003; Patel et al., 
2009), to determine if exposing mitochondria to low DNP doses 
(1.0–10.0 μM) were age- or injury-dependent. A significant uncoupling 
effect emerged at 10.0 μM DNP in mitochondria obtained from unin-
jured mice at both 3- (F(2,4) = 24.86, p < 0.01; Fig. 1C) and 7-dpi (F =
(2,4) = 85.46, p < 0.005; Fig. 1D). After SCI however, only mitochondria 
isolated from 14-MO injured-mice were responsive to low DNP doses at 
3 dpi (p < 0.005)(Fig. 1). By 7 dpi, all mitochondrial populations 
responded to low doses of DNP, confirming that injury induced deficits 
were no longer detectable (p < 0.005)(Fig. 1). Here we observed that 
mitochondrial responses to treatment after injury are age dependent and 
that older mitochondria surprisingly maintain a higher sensitivity to 
mitochondrial uncoupling. This age-dependent effect of isolated mito-
chondria to mild uncoupling led us to hypothesize that an optimal DNP 
dose for treating SCI in vivo may differ with age. 
Fig. 1. Ex vivo uncoupling of isolated mitochondria with DNP exert age-dependent effects. Mitochondria were isolated from 4- and 14-MO mice at 3- and 7-days post 
sham (laminectomy) or spinal cord injury (SCI). Graded doses of DNP were administered to determine the efficiency of generating an uncoupling response. At 3- days 
post-injury (DPI) maximum respiratory capacity was lower in mitochondria obtained from SCI- compared to sham-mice (A), no injury effect was detectable by 7-DPI 
(B). All groups exhibited a significant uncoupling response upon administration of 10 μM DNP at 3-DPI (p < 0.005) except mitochondria obtained from 4-MO SCI- 
mice (C). This age-dependent response was ameliorated by 7-DPI where all groups exhibited a significant uncoupling response upon administration of 10 μM DNP (p 
< 0.005; D). Analyzed using two-way ANOVA. Graphs represent mean ± SEM, n = 3/group. *p < 0.05, ***p < 0.005 vs vehicle (A, B) or vs baseline (C, D). 
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3.2. A low dose of DNP is toxic to 4-MO- but protective to 14-MO-SCI 
mice at 7-DPI 
To determine if age-dependent uncoupling persists in vivo after SCI, 
we treated 4- and 14-MO SCI mice with graded doses of DNP for 7-dpi 
and examined outcomes associated with mitochondrial dysfunction: 
oxidative damage, neuron survival, and tissue sparing. Previous work 
from our lab has identified the greatest age-dependent accumulation of 
oxidative damage at 7-dpi (Zhang et al., 2016, 2015). Further, we found 
that 14-MO mice experience greater loss of tissue surrounding SCI le-
sions associated with this age-dependent increase in ROS (Zhang et al., 
2019, 2016, 2015). For mid-thoracic SCI, tissue sparing surrounding the 
lesion strongly correlates to functional outcomes and therefore was 
investigated as a merit to an overall treatment effect of DNP (Basso et al., 
1996). 
To delineate the contribution of mitochondrial-derived ROS to 
exacerbated tissue loss with age, we evaluated a dose-dependent 
response of mild-uncoupling using DNP for 7-dpi. DNP doses were 
chosen in accordance with prior literature citing a therapeutically 
effective range from 1.0- to 5.0-mg/kg in young rodents (Maragos et al., 
2003; Patel et al., 2009). Consistent with our previous work finding 
increased ROS damage (4-HNE) in 14- compared to 4-MO mice at 7 dpi 
(Zhang et al., 2016), here we found an age-dependent increase in 3-NT 
accumulation (F(1,30) = 5.31, p < 0.05; Fig. 2B). Further, we found that 
the lowest DNP dose (1.0-mg/kg/day) significantly reduced 3-NT 
accumulation only in 14-MO mice relative to vehicle controls (p <
0.05; Fig. 2B), demonstrating consistency with ex vivo analyses indi-
cating that 14-MO injured-mitochondria are responsive to low DNP 
doses (Fig. 1). DNP treatment was ineffective at reducing oxidative 
damage in 4-MO mice regardless of dose (Fig. 2B). When results from 14- 
and 4-MO mice were compared directly by normalizing to vehicle con-
trols within each age, no significant effects were found (Fig. 2C). 
Next, effects of DNP treatment on neuron survival and tissue sparing 
were assessed within each age. For neuron sparing, 14-MO SCI mice 
treated with DNP displayed no overall effects (F(3,15) = 2.05, p = 0.15; 
Fig. 3B). Higher doses trended towards neuron toxicity but did not reach 
significance (p = 0.14; Fig. 3B). In contrast, spinal cords from 4-MO mice 
treated with DNP displayed an acute toxic response apparent through a 
significant loss of neurons surrounding the lesion (F(3,12) = 9.16, p <
0.005) at all DNP doses (p < 0.05; Fig. 3B). There were dose-dependent 
differences in tissue sparing in 14-MO SCI mice (F(3,16) = 2.88, p = 0.06; 
Fig. 4B) with the 1.0-mg/kg/day dose varying significantly from vehicle 
(Dunnett’s pairwise comparison, p = 0.05). There was no effect of higher 
DNP doses on tissue sparing in 14-MO mice (p = 0.92), and no effects on 
spared tissue were found in 4-MO mice (F(3,14) = 1.21, p = 0.34; Fig. 4B). 
Comparing the absolute values of neuron survival and tissue sparing 
Fig. 2. The biomarker of reactive oxygen 
species production, 3-NT, is reduced in 14- 
MO mice treated with DNP at 7 days after 
spinal cord injury. DNP was provided at 1.0-, 
2.5-, or 5.0-mg/kg/day for 7 days to 4- and 
14-MO mice after SCI to determine the ef-
fects of uncoupling on accumulation of 
oxidative stress. Immunohistochemistry was 
performed to label nitrotyrosine (3-NT) ad-
ducts that are indicative of upstream reac-
tive oxygen species production. The 3-NT 
labeled tissue surrounding the lesion was 
analyzed as a percentage of the total cross 
sectional area of the cord. Images of repre-
sentative samples 500 μm away from the 
lesion epicenter (A) reveal a significant in-
crease in 3-NT expression in 14-MO mice 
after SCI (p < 0.05; B). A 1.0 mg/kg/day 
dose of DNP significantly reduced 3-NT 
accumulation only in 14-MO mice after SCI 
(p < 0.05; B). When compared to vehicle- 
treated mice, no significant differences 
were found in a treatment effect with DNP 
between 4- and 14-MO mice (p = 0.09; C). 
Scale bar represents 500 μm. Analyzed using 
two-way ANOVA. Graphs represent mean ±
SEM, n = 3-5/group. *p < 0.05.   
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Fig. 3. DNP exerts toxic effects on neuron survival in 4-MO mice at 7 days after spinal cord injury. Tissue obtained from mice at 7-DPI was analyzed for effects of 
DNP on neuron survival. Images of representative samples taken at 500 μm away from the lesion epicenter (A) demonstrate a significant loss of neurons with all DNP 
doses in 4- but not 14-MO mice (p < 0.05 for 1.0- and p < 0.005 for 2.5- and 5.0-mg/kg; B). When compared to vehicle-treated mice, no differences were found in a 
treatment effect with DNP between 4- and 14-MO mice (p = 0.08; C). Scale bars represent 500 μm. Boxes represent analysis regions over the ventral horns, and 
enlarged images. Arrows point to the central canal. Analyzed using one-way ANOVA for each age (B) or two-way ANOVA (C). Graphs represent mean ± SEM, n = 3- 
5/group. *p < 0.05, ***p < 0.005 vs. vehicle control. 
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between 4- and 14-MO mice is technically inappropriate because the 
spinal cord size increases with musculoskeletal maturity over the first 
7–8 months of age (Quinn, 2005). This can make an increased absolute 
area of spared tissue in 14-MO, relative to 4-MO mice, proportionally 
less compared to pre-injury values. Comparing tissue sparing between 
ages is therefore compromised due to inherent size differences of the 
spinal cord. An apparent increase in neurons surrounding the lesion in 
14-MO mice was, however, unexpected. We do not yet know if this is a 
biological response or a technical artifact similar what was described for 
tissue sparing, however, this effect was reproduced at 28-DPI and can be 
found below (Fig. 6). 
In consideration of the technical limitations of directly comparing 
effects of DNP on neuron survival and tissue sparing between ages, we 
normalized values to age-matched vehicle-treated controls. We observed 
no significant effects (F(2,19) = 3.38, p = 0.08; Fig. 3C) of age on neuron 
toxicity but did observe a significant age-divergent response to DNP 
treatment in spared tissue surrounding the lesion (F(1,21) = 13.72, p <
0.001; Fig. 4C). Post hoc analyses revealed a significant increase in tissue 
sparing in 14- compared to 4-MO mice treated with 1.0- (p < 0.01) and 
2.5-mg/kg/day DNP (p < 0.05) relative to their respective vehicle- 
treated controls (Fig. 4C). Together, these data support our ex vivo 
findings of mitochondria from 14-MO SCI-mice being more responsive 
to mild uncoupling. Further, our data demonstrate that age has a pro-
found effect on mitochondria-mediated neurodegeneration as indicated 
by opposite treatment effects in 14- and 4-MO SCI-mice. 
4. DNP maintains age-divergent effects at 28-DPI 
Due to fluctuating events acutely within the injured microenviron-
ment, recovery from injury can take weeks to stabilize (Basso et al., 
2006; Detloff et al., 2012; Silva et al., 2014). Previously we reported that 
acute mitigation of ROS production in 14-MO SCI-mice leads to 
improved and stabilized recovery by 3–4 weeks post-injury (Zhang et al., 
2019). Therefore, we examined functional and anatomical recovery for 
28-dpi to determine long-term effects of DNP treatment on SCI neuro-
pathology and functional outcomes. Because data obtained at 7-dpi was 
inconsistent with prior literature that suggests a 5.0-mg/kg/day dose of 
DNP is most protective (Jin et al., 2004; Patel et al., 2009), we utilized 
both a 5.0- and 1.0-mg/kg/day dose that appeared most efficacious in 
14-MO mice. 
As reported previously, we observed a significant effect of age on 
locomotor outcomes after SCI with 14-MO mice having significantly 
impaired over ground (BMS; F(1,49) = 15.18, p < 0.0005; Fig. 5A) and 
proprioceptive (horizontal ladder; F(2,47) = 12.21, p < 0.001; Fig. 5C) 
locomotor function relative to 4-MO mice (Zhang et al., 2019, 2016, 
2015). There were no interactions among treatment and age on the 
horizontal ladder. A significant three-way interaction (F(8,199) = 2.01, p 
< 0.05) was found for motor recovery on open field BMS analysis, 
suggesting a differential response to DNP with age (Fig. 5A). Specif-
ically, 14-MO mice treated with either 1.0- or 5.0-mg/kg/day had sig-
nificant improvements in overt locomotion (BMS scores; p < 0.05) 
Fig. 4. DNP exerts age-divergent effects on 
tissue sparing at 7 days after spinal cord 
injury. The extent of tissue sparing was 
assessed at 7-DPI after treatment with DNP. 
Images of representative samples of lesion 
epicenters (A) demonstrate that treatment 
with 1.0-mg/kg/day DNP spared tissue in 
14- but not 4-MO mice treated (p < 0.05; B). 
When compared to same age vehicle-treated 
groups, the 1.0- and 2.5-mg/kg/day DNP 
doses resulted in significant age divergent 
responses by reducing tissue sparing in 4- 
MO SCI mice and preserving tissue in 14- 
MO SCI mice (C). Scale bars represent 500 
μm. Analyzed using one-way ANOVA for 
each age (B) or two-way ANOVA (C). Graphs 
represent mean ± SEM, n = 3–5/group. *p 
< 0.05, **p < 0.01, ***p < 0.001.   
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compared to vehicle treated mice. In contrast, 4-MO mice treated with 
1.0-mg/kg/day DNP demonstrated toxicity apparent through signifi-
cantly worse motor recovery by 21-dpi in measures of both overt loco-
motion (BMS; p < 0.005) and finer details of hindlimb and locomotor 
function (BMS sub-scores; p = 0.01; Fig. 5B). Similar to data obtained at 
7-dpi, significant age-divergent effects were apparent in BMS scores 
(F(1,34) = 10.44, p < 0.01) for mice treated with 1.0-mg/kg/day of DNP 
(p < 0.005) after normalizing values to age-matched vehicle-treated 
Fig. 5. DNP exerts age-divergent effects on motor functions after spinal cord injury. DNP treatment (1.0-mg/kg/day for 7 days after injury) significantly reduced 
motor function by 28-DPI in 4-MO SCI mice (p < 0.005) but improved recovery in 14-MO SCI mice (p < 0.05) when analyzed with BMS motor score (A,D). A 
significant improvement in BMS scores was also observed in 14-MO, but not 4-MO, mice treated with 5.0-mg/kg/day (p < 0.05; A). Similar effects were observed for 
BMS sub-scores in 4- but not 14-MO mice by 28-DPI (p < 0.01; B). A main effect of age was observed for foot-slips on horizontal ladder (p < 0.005) but no effects were 
found for treatment with DNP (C). Age-divergent effects were apparent at 28-DPI on BMS scores when compared to age-matched vehicle-treated mice at both 1.0- (p 
< 0.005) and 5.0 mg/kg/day doses (p < 0.05; D). Analyzed using Three-way ANOVA with repeated measures (A, B) or two-way ANOVA (C, D). Graphs represent 
mean ± SEM, n = 8-10/group for BMS and BMS sub-score and n = 6–10/group for horizontal ladder. *p < 0.05, **p < 0.01, ***p < 0.005, vs same day 
vehicle controls. 
A.N. Stewart et al.                                                                                                                                                                                                                              
Experimental Neurology 337 (2021) 113597
9
mice (Fig. 5D). Specifically, on average 14-MO SCI-mice improved by 
>25% relative to vehicle-treated mice, while locomotor function in 4- 
MO SCI mice decreased by ~25% (Fig. 5D). 
With regards to long term neurodegenerative outcomes, no signifi-
cant effects were detected for treatment on neuron survival (4-MO 
F(2,26) = 0.59, p = 0.55; 14-MO F(2,24) = 1.56, p = 0.23; Fig. 6A, B), or 
axon sprouting at 28-dpi (4-MO F(2,26) = 3.17, p = 0.058; 14-MO F(2,24) 
= 2.22, p = 0.12)(Fig. 6C, D). Not observing a similar toxic effect on 
neurons at 28-dpi, as we did at 7-dpi, suggests that DNP accelerated the 
death of neurons that were likely going to experience a delayed death 
after injury alone. However, locomotor recovery after SCI is more 
closely associated with the extent of tissue sparing surrounding the 
lesion, particularly at the lesion epicenter (Basso et al., 1995). Consistent 
with our observations of age-divergent effects of DNP treatment on lo-
comotor function, we observed that DNP exerts an overall toxic effect on 
tissue sparing at the lesion epicenter in 4- (F(2,26) = 3.804, p < 0.05) but 
not 14-MO SCI-mice (F(2,24) = 0.11, p = 0.89; Fig. 7B). Specifically, DNP 
exacerbated tissue loss at the lesion epicenter in 4-MO mice treated with 
1.0- (p < 0.05), but not 5.0-mg/kg/day (p < 0.15; Fig. 7B), as well as, an 
overall loss of tissue extending 700 μm rostral and caudal to the 
epicenter (p < 0.05)(Fig. 7). No differences were found for the rostral- 
caudal length of lesion (4-MO F(2,26) = 0.46, p = 0.63; 14-MO F(2,24) 
= 1.46, p = 0.25; Fig. 7C), or when evaluating tissue sparing with 
repeated measures over a 7 mm span of sectioned tissue (4-MO F(2,26) =
1.464, p = 0.25; 14-MO F(2,24) = 0.27, p = 0.76) in either age (Fig. 7E). 
Comparing spared tissue in DNP-treated mice relative to vehicle- 
treated mice between ages revealed that DNP exerts an overall signifi-
cant age-dependent toxicity to 4-MO mice (F(1,33) = 8.79, p < 0.01), with 
~25% decrease in tissue sparing with each dose (1.0-mg/kg/day, p =
0.07; 5.0-mg/kg/day, p = 0.09) (Fig. 7D). DNP treatment did not vary 
Fig. 6. DNP does not exert significant effects on neuron survival or axon sprouting at 28 days after spinal cord injury. Toxic effects of DNP on neurons were 
normalized by 28-DPI, similarly no significant effects were found for axon sprouting. Images of representative samples obtained at 500 μm rostral to the lesion 
epicenter (A) or at the lesion epicenter (C) demonstrate no differences in neuron survival (B) or axon sprouting in the lesion (D). Scale bars represent 100 μm (C) and 
500 μm (D). Analyzed using one-way ANOVA for each age. Graphs represent mean ± SEM, n = 8–10/group. 
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significantly from vehicle controls in 14-MO SCI mice. Together with our 
data from 7-dpi, our results show that acute age differences in mito-
chondrial responses to injury manifest in long term functional deficits 
and neurodegeneration in an age-divergent manner. 
5. In vivo DNP significantly reduces complex I mediated 
respiration in aged mice 
Having replicated age-divergent effects of treating SCI-mice with 1.0 
mg/kg DNP at both 7- and 28-dpi, we sought to investigate how in vivo 
DNP treatment affects mitochondrial functions. We isolated mitochon-
dria from 4- and 14-MO mice receiving either sham-, SCI + vehicle, or 
SCI + 1.0 mg/kg/day DNP for either 3- or 7-days after SCI. Seahorse was 
used to determine respiratory efficiency in State III and State IV respi-
ration, as well as to test for complex I and II mediated electron transport. 
ATP-linked respiration was calculated by subtracting State III from State 
IV respiration to control for non-respiratory oxygen consumption. 
Coupling efficiency was also calculated using respiratory control ratios 
(RCR; State III/State IV). 
While no significant interactions were found, effects of DNP on 
mitochondrial functions persisted to display an age divergent trend at 3- 
DPI, only in an unexpected direction. DNP appeared to further exacer-
bate SCI-induced mitochondrial deficits in 14-MO mice, and signifi-
cantly impaired complex I mediated electron transport compared to 
sham controls (p < 0.05; Fig. 8A). No other significant effects were found 
at 3-dpi (Fig. 8A–C) and no injury or treatment effects were observed at 
7-dpi (Fig. 8D–F), however, ATP linked-respiration was decreased as a 
main effect of age as previously reported (F(1,12) = 4.97, p < 0.05; 
Fig. 8D; (Yonutas et al., 2015)). While the implications of a reduced 
complex I capacity may appear detrimental at first, this may result in 
less produced ROS from a lowered metabolic activity. This would be 
consistent with our findings that 1.0 mg/kg/day DNP attenuated 3-NT 
accumulation in 14-MO mice. 
6. Discussion 
As life expectancies increase, age-associated declines in cellular 
processes play an increasing role in the pathophysiology of neurode-
generative conditions. Interactions between how age affects tissue re-
sponses in injury and disease will likely have unique consequences on 
therapeutic strategies. Without considering age as a variable in clinical 
or pre-clinical studies, it will be difficult to predict how biological pro-
cesses respond to insults across the lifespan. Neurotrauma is specifically 
affected by age, as traumatic brain injury (TBI) exacerbates age- 
associated neurodegeneration (i.e. chronic traumatic encephalopathy) 
and the demographic of spinal cord injury (SCI) is shifting to older in-
dividuals sustaining injuries. 
The major aim of this study was to determine how aging effects 
mitochondrial regulation of neurodegeneration in a mouse model of SCI. 
We found that mild mitochondrial uncoupling exerts age-divergent ef-
fects, ultimately resulting in improvements in function in 14-MO (month 
old) SCI-mice but further impairing function of 4-MO SCI-mice. Specif-
ically, we observed that after SCI, age increases the sensitivity of isolated 
mitochondria to ex vivo uncoupling using DNP. In vivo, we observed that 
DNP reduced neuron and white matter survival in 4-MO SCI-mice, but 
the same dose had protective effects in 14-MO SCI-mice and reduced 
protein nitration. This age-divergent response to DNP manifested as 
long-term impairments in tissue preservation and locomotor function in 
Fig. 7. DNP reduces tissue sparing in 4-MO mice at 28 days after spinal cord injury. Lesion sizes stabilize by 28-DPI, which revealed a sustained toxic effect of DNP on 
tissue preservation to 4-MO mice, with no effects occurring in 14-MO mice. Lesion epicenter images representative of group means (A) demonstrate a significant 
reduction in tissue sparing in 4- but not 14-MO SCI mice treated with 1.0-mg/kg/day (for 7 days after SCI) of DNP (B). Treating SCI mice with 1.0-mg/kg/day of DNP 
reduced spared tissue spanning the lesion up to 700 μM rostral and caudal to the epicenter in 4-MO animals compared to vehicle-treated controls (p < 0.05). Overall 
effects of DNP treatment exerted an age-dependent toxic response that reduced tissue sparing significantly in 4-MO mice with no effects on 14-MO mice (p < 0.01; D). 
Scale bars represent 500 μm. Analyzed using one-way ANOVA for each age (B,C), two-way ANOVA (D), or two-way ANOVA with repeated measures for each age (E). 
Graphs represent mean ± SEM, n = 8–10/group. *p < 0.05, **p < 0.01. 
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4-MO SCI-mice with contrasting improvements in 14-MO mice. Finally, 
in vivo treatment with DNP reduced complex I mediated electron 
transport only in isolated 14-MO injured mitochondria, but preserved 
coupling efficiency (RCR) relative to mice receiving SCI and vehicle. A 
decrease in respiratory capacity when RCR is preserved can be indica-
tive of lower global electron transport activity. Under these conditions’ 
mitochondria may reduce ROS production, which might underly why 
DNP decreased 3-NT accumulation only in 14-MO mice. Our findings 
point to the endogenous regulation of mitochondrial function as an 
important mediator of recovery at younger ages that shifts towards a 
contributor of pathology with advanced age. Further, our findings 
emphasize a need to consider the age dependence of therapeutic 
Fig. 8. DNP lowers complex I-mediated electron transport with a preserved coupling efficiency in 14-MO mitochondria at 3-DPI. Mitochondria were isolated from 
mice receiving sham-, SCI-, and SCI + 1.0 mg/kg/day DNP at 3- (A–C) and 7-DPI (D–F), and evaluated for bioenergetic capacity using a mitochondrial stress test on 
Seahorse. The difference between mitochondrial state III and IV was used to evaluate ATP-linked respiration (B, E) and the ratio was used to calculate RCR as a 
measure of coupling efficiency (C, F). Complex I and II mediated electron transport were determined during State V respiration. DNP significantly impaired complex I 
mediated electron transport relative to sham-controls in 14-MO mice (p < 0.05), with SCI-only exerting an insignificant intermediate effect (p = 0.26 vs sham). DNP 
exerted insignificant trends towards an overall reduction in oxygen consumption and ATP-linked respiration further away from sham values relative to SCI-only at 3- 
DPI in 14-MO mice, however, DNP did not further reduce RCR coupling efficiency. DNP treatment or SCI-alone exerted no significant effects at 7-DPI, but main effects 
of age reduced ATP-linked respiration (p < 0.05). Each outcome was analyzed using two-way ANOVA with Tukey’s post hoc used for pairwise comparisons within 
each age. Graphs represent mean ± SEM, n = 3/group. 
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interventions targeting SCI as well as various other neurodegenerative 
conditions. 
As knowledge of neurological disorders advance, diagnostic capa-
bilities are becoming available at earlier stages of disease. Moving for-
ward it will be of vital importance to consider age at the time of 
treatment as a variable in our efforts to advance personalized medicine. 
If similar interactions exist in other neurological conditions or with 
different drugs, our data indicate that intervention at too early an age 
can possibly accelerate disease progression. Researchers often utilize 
accelerated animal models of disease such as the 3xTg mouse model of 
Alzheimer’s disease, the R6/2 model of Huntington’s disease, or the 6- 
hydroxydopamine model of Parkinson’s disease to understand neuro-
logical conditions of aging (Hernandez-Baltazar et al., 2017; Li et al., 
2005; Sterniczuk et al., 2010). Our findings indicate that interactions 
between an animals age and induced onset of disease may confound 
interpretations of how mitochondria contribute to pathogenesis and 
challenge the translatability of treatment strategies into clinical pop-
ulations. In particular, discontinuities in ages used for pre-clinical stroke 
studies compared to patients enrolled in clinical trials is increasingly 
implicated in the widespread failure to translate therapies (Ay et al., 
2005; Badan et al., 2003; Cheng et al., 2009; Herson and Traystman, 
2014; Pennypacker et al., 2017). 
Within the field of neurotrauma our findings have far reaching im-
plications. First, clinical demographics are progressing towards an 
increased average age at time of SCI (NSCISC, 2013; Toda et al., 2018). 
Yet, when evaluating the therapeutic potential of drugs in clinical 
populations, age is often not considered as a variable underlying treat-
ment efficacy. To date the only drug used to treat SCI is methylpred-
nisolone, which functions predominately to suppress injury-induced 
inflammation (Bracken et al., 1990, 1997). Efficacy of methylprednis-
olone as a treatment for SCI has been under scrutiny and is falling out of 
use due to complications associated with immune suppression. How-
ever, advancements in rodent models of SCI have recently demonstrated 
that treatments targeting ROS and inflammation may exert effects in 
older rodents even when little effects are found at younger ages (Zhang 
et al., 2019). This should merit re-evaluation of clinical data to deter-
mine if the effectiveness of previously investigated drugs targeting ROS 
exert improved efficacy with age (Stewart et al., 2019). 
Given the resilience of younger individuals to neurological recovery 
after trauma or disease, one would predict that an increased age at time 
of injury would decrease treatment-mediated recovery. Unexpectedly, in 
the current study, we found that age increased the sensitivity of isolated 
injured mitochondria to ex vivo uncoupling with DNP, and found that 
DNP exerts reciprocal effects to 4- and 14-MO mice after SCI. As we and 
others have demonstrated, this may be due to ROS playing a larger role 
in the pathophysiology of SCI with advanced age (von Leden et al., 2017; 
Zhang et al., 2016). Due to the juxtaposing nature of mitochondrial 
uncoupling by decreasing both ROS and ATP, what can be derived from 
our work is that net contributions of mitochondrial function after SCI 
progress towards a more pathological role with advancing age in part by 
increasing free radical damage. 
The mechanisms underlying the age-divergent effects found in this 
study remain unknown. While cellular toxicity caused by decreased ATP 
is possible, there is little evidence to suggest that mild uncoupling using 
doses in this study would exert a major energy crisis. Rodent studies in 
Huntington’s disease have used repeated dosing of DNP at 1.0 mg/kg/ 
day and found beneficial effects on the progression of the disease (Wu 
et al., 2017); however, repeated dosing at 5.0 mg/kg did inevitably 
result in toxic effects. This contrasts our study that demonstrated the 
higher 5.0 mg/kg dose of DNP was less toxic than a lower 1.0 mg/kg 
dose to 4-MO mice. Since DNP uncouples mitochondria in a dose- 
dependent manner (Fig. 1), and a higher dose of DNP was less toxic in 
our study, there are likely alternative mechanisms to a major energy 
crisis that can explain the observed age-divergent trends. 
One possible mechanism to explain our age-divergent effects may be 
attributed to a decreased calcium uptake by mitochondria treated with 
DNP (Sedlic et al., 2010). Glutamate-induced excitotoxicity occurring 
after SCI induces high cellular influx of Ca2+ which is buffered by 
mitochondria. At a certain Ca2+ influx threshold, the mitochondrial 
permeability transition pore (mPTP) opens and floods the cytoplasm 
with Ca2+, collapses the membrane potential, and expels NAD(H) 
(Nicholls and Ward, 2000). Whereas transient opening of the mPTP can 
be a physiological regulator of ROS production, sustained opening of the 
mPTP swells the outer mitochondrial membrane, causing release of 
cytochrome C into the cytoplasm and initiation of apoptotic cascades 
(Huang et al., 2001). Our data found that older and injured mitochon-
dria uncouple at lower DNP doses, which may confer a greater resistance 
to mitochondrial Ca2+ uptake in 14-MO SCI-mice. Under these circum-
stances, any modest toxicity associated with decreased ATP production 
may be counter-balanced by a therapeutic capacity to reduce Ca2+ up-
take and limit opening of the mPTP. 
A decreased Ca2+ uptake by mitochondria can result in greater 
cytosolic Ca2+ and lead to downstream activation of transcriptional 
activity. Additionally, while Ca2+-induced gene regulation is probable 
following DNP administration, effects of DNP have been affiliated with 
upregulated cAMP-associated genes independent of Ca2+ signaling 
(Sebollela et al., 2010). Effects found by Sebollela et al. (2010) are 
particularly intriguing because the in vitro DNP doses used were low 
enough to not impact mitochondrial oxygen consumption. This dem-
onstrates that DNP doses in the mild-uncoupling range can exert off- 
target effects. Due to the function of DNP as being both a weak acid 
and very membrane permeable, it is likely that other organelles that 
function on pH gradients, such as lysosomes, may be affected by mito-
chondrial uncouplers (Andres et al., 1996). In the context of aging, 
lysosome dysfunction has been affiliated with detrimental autophagic 
abilities (Mattson and Arumugam, 2018). If DNP does exert effects on 
lysosomal function, it may be possible for sustained delivery of DNP to 
exert age-divergent cellular effects from mechanisms independent of the 
mitochondria, however this has not been examined. 
Our results indicating that DNP exerts toxic effects to 4-MO mice 
contrasts with our previous work demonstrating therapeutic effects in 
young rats after SCI (Jin et al., 2004; Patel et al., 2009). Besides use of a 
different species, the most notable methodological discrepancies be-
tween this work and previous reports were in dosing paradigms. Spe-
cifically, our previous work with DNP performed in rat models of SCI 
utilized either a single pre-treatment or a single acute dose (Jin et al., 
2004; Patel et al., 2009), whereas this study utilized daily doses for 1- 
week post-injury with a 30-min delay from time of injury to adminis-
tration. DNP has been administered daily for extended periods of time as 
a treatment in other animal models of neurodegenerative diseases with 
improved outcomes found after TBI, Alzheimer’s disease, Parkinson’s 
disease, Huntington’s disease, as well as promoting overall longevity of 
life (Caldeira da Silva et al., 2008; De Felice and Ferreira, 2006; Hubbard 
et al., 2018; Lee et al., 2017; Wu et al., 2017). This led us to believe that 
multiple doses may exert additional protective effects following SCI, 
however this may not have been the case for younger 4-MO mice. It 
remains critical for future studies to evaluate the effects of sustained, 
compared to acute, mitochondrial uncoupling on recovery from neuro-
trauma to better elucidate the role of mitochondria on both injury and 
repair. Further, our data highlights potential metabolic differences with 
age that change the net effects of DNP, which merits further investiga-
tion into the pharmacodynamic interaction between age and bio- 
availability within the cord. 
Finally, it is important to note that mitochondrial function is 
differentially regulated spatially within the nervous system (Sullivan 
et al., 2004; Yonutas et al., 2015), temporally following injury (Thawer 
et al., 2013), with cellular specificity (Fecher et al., 2019; Hubbard et al., 
2019; Patel et al., 2009), and potentially in a species-specific manner. 
Not all cells are affected the same by age which could result in a dif-
ferential response to DNP in a cell- and aging-dependent interaction. For 
example, increasing evidence indicates that mitochondrial function 
regulates macrophage and microglia phenotype (Devanney et al., 2020) 
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and we observed that the macrophage response to SCI increases with age 
(Zhang et al., 2019). The extent to which age and mitochondrial func-
tion of macrophages contributes to the current results requires further 
investigation. Further, aging alone has been attributed to an increase in 
mitochondrial-derived ROS that is dependent upon cell type and may 
differentially be affected by DNP. Even within a species subtle genetic 
differences can exert large effects on mitochondrial function (Gameiro 
et al., 2013; Ripoll et al., 2012). What can be concluded from the current 
study is that the influence of mitochondrial function following SCI also 
depends on age. Understanding how age effects the spatial, temporal, 
cellular, and species specificity of mitochondrial functions remains to be 
elucidated and may be essential for successful translation of 
mitochondrial-targeting therapeutic strategies. 
7. Conclusions 
In conclusion, increased age at time of SCI shifts the response of mild- 
mitochondrial uncoupling using repeated dosing of DNP from a net 
toxicity towards therapeutic efficacy. Mechanisms of how increased age 
changes cellular responses to uncoupling remains to be determined, 
however, delineating contributions of mitochondrial membrane poten-
tial to SCI injury and repair can effectively be investigated through 
pharmacological delivery of DNP. Results from the current study reit-
erate that age at time of SCI can significantly change treatment out-
comes (Stewart et al., 2019; Zhang et al., 2019) re-enforcing a need to 
consider age as a biological variable in studies of neurological disorders. 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.expneurol.2021.113597. 
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